Analysis of the Clinical Effects of the Combination of Mycophenolate Mofetil with Either Tacrolimus or Cyclophosphamide

Zhang, Xuebing; Liu, Pei; Zhang, Zhen

doi:10.6061/clinics/2020/e1820

Cited by 3 publications

(1 citation statement)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…8,9 Moreover, multitarget therapy has demonstrated signi cant e cacy in LN patients, and TAC is often used in combination with mycophenolate mofetil (MMF) and cyclophosphamide (CYC). [10][11][12] The combination therapy of TAC with other drugs can reduce dosages of TAC and other drugs, as well as drug-related organ damage and infections. [13][14][15] Multiple clinical studies have shown that the treatment regimen combining TAC with MMF or CYC has signi cant renal therapeutic effects for LN patients who have failed to respond to monotherapy.…”

Section: Introductionmentioning

confidence: 99%

The effect of tacrolimus combined with mycophenolate mofetil or cyclophosphamide on renal response in systemic lupus erythematosus patients

Sun,

Zhang,

Guo

et al. 2024

Preprint

View full text Add to dashboard Cite

Objective This study aimed to determine the therapeutic effect of tacrolimus (TAC) and its combination with mycophenolate mofetil (MMF) or cyclophosphamide (CYC) on the complete response (CR) in patients with systemic lupus erythematosus (SLE). Methods A retrospective cohort study based on medical data was conducted among SLE patients taking at least one of TAC, MMF and CYC during 2010–2021. Odds ratio (OR) and 95% confidence interval (CI) were calculated and multiplicative interactions were estimated using logistic regression models. Results Among 793 SLE patients, 27.9% (221 cases) patients achieved CR after at least 3 months. TAC use was positively associated with CR with adjusted OR (95% CI) of 2.82(1.89, 4.22) in overall, as well as in subgroups of SLE patients with SLEDAI score > 12, moderate or severe urinary protein and comorbidities. The dose-response effect on CR was further observed at the dose of TAC more than 4 mg/d and more than 180 days, with adjusted OR (95% CI) of 5.65(2.35, 13.55), and 3.60(2.02, 6.41) respectively. Moreover, the combined effect of TAC with MMF or CYC was better than monotherapy with the significant multiplicative interaction, with adjusted OR (95% CI) of 2.43(1.20,4.92) and 3.14(1.49,6.64), respectively, and similar results were also observed for the combination of different doses of TAC with MMF or CYC. Conclusion TAC can effectively alleviate the condition of patients with SLE and may interact with MMF or CYC, suggesting that the combination therapy of TAC with MMF or CYC may produce greater benefits for patients with SLE. Trial registration: This is a purely observational study that does not require registration.

show abstract

Section: Introductionmentioning

confidence: 99%

The effect of tacrolimus combined with mycophenolate mofetil or cyclophosphamide on renal response in systemic lupus erythematosus patients

Sun,

Zhang,

Guo

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

KDIGO 2024 Clinical Practice Guideline for the management of LUPUS NEPHRITIS

Rovin,

Ayoub,

Chan

et al. 2024

Kidney International

View full text Add to dashboard Cite

KDIGO 2024 Clinical Practice Guideline for the management of lupus nephritis. Translated into Russian by E.V. Zakharova

Editorial

2024

jour

View full text Add to dashboard Cite

The Kidney Disease: Improving Global Outcomes (KDIGO) 2024 Clinical Practice Guideline for the Management of Lupus Nephritis represents a focused update of the Lupus nephritis chapter from the KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. The aim is to assist clinicians caring for individuals with lupus nephritis. The update takes into consideration evidence from randomized controlled trials published since February 2022. As in 2021, the chapter follows the same template, providing guidance related to diagnosis, treatment, and special situations. Based on the evidence, this update is focused on guidance related to treatment of lupus nephritis. This guideline update followed an explicit process of evidence review and appraisal. Treatment approaches and guideline recommendations are based on systematic reviews of relevant studies, and appraisal of the strength of recommendations and certainty of the evidence following the “Grading of Recommendations Assessment, Development and Evaluation” (GRADE) approach. Limitations of the evidence are discussed and areas of future research are presented.

show abstract

Analysis of the Clinical Effects of the Combination of Mycophenolate Mofetil with Either Tacrolimus or Cyclophosphamide

Cited by 3 publications

References 23 publications

The effect of tacrolimus combined with mycophenolate mofetil or cyclophosphamide on renal response in systemic lupus erythematosus patients

The effect of tacrolimus combined with mycophenolate mofetil or cyclophosphamide on renal response in systemic lupus erythematosus patients

KDIGO 2024 Clinical Practice Guideline for the management of LUPUS NEPHRITIS

KDIGO 2024 Clinical Practice Guideline for the management of lupus nephritis. Translated into Russian by E.V. Zakharova

Contact Info

Product

Resources

About